Get the Stockscreener App
13.68
2.70%
-0.38
After Hours:
13.69
0.010
+0.07%
Olema Pharmaceuticals Inc stock is traded at $13.68, with a volume of 1.06M.
It is down -2.70% in the last 24 hours and down -15.76% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$14.06
Open:
$13.89
24h Volume:
1.06M
Relative Volume:
0.73
Market Cap:
$1.19B
Revenue:
-
Net Income/Loss:
$-185.15M
P/E Ratio:
-6.7546
EPS:
-2.0253
Net Cash Flow:
$-148.72M
1W Performance:
+0.66%
1M Performance:
-15.76%
6M Performance:
-40.96%
1Y Performance:
+165.12%
1-Day Range:
$13.20
$14.29
1-Week Range:
$12.63
$14.29
52-Week Range:
$3.89
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
13.68 | 1.23B | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Peer Perform |
| Mar-19-26 | Resumed | Jefferies | Buy |
| Feb-11-26 | Initiated | Stifel | Buy |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap - Yahoo Finance
OLMA Sees Early Tumor Shrinkage in Phase 1 OP-3136 Study, Stock Gains Pre-Market - Stocktwits
Olema Oncology sees early hope as cancer drug shows tumor shrinkage in phase 1 study - MSN
Olema Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:OLMA - Benzinga
Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study - Yahoo Finance
H.C. Wainwright reiterates Olema Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Olema Oncology Reports Promising Phase 1 Results for OP-3136 KAT6 Inhibitor in Advanced Solid Tumors at 2026 ASCO Meeting 12 - Minichart
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting - Sahm
Olema reports phase 1 data for cancer drug OP-3136 By Investing.com - Investing.com South Africa
Olema reports phase 1 data for cancer drug OP-3136 - Investing.com UK
Olema Pharmaceuticals Reports Promising Initial Data for OP-3136 in Phase 1 Study Evaluating KAT6 Inhibitor for Advanced Solid Tumors - Quiver Quantitative
Olema Oncology (NASDAQ: OLMA) shares early OP-3136 Phase 1 cancer data - Stock Titan
Early cancer trial sees tumor shrinkage in 13 of 19 on Olema drug - Stock Titan
Olema Pharmaceuticals (OLMA) Valuation After Encouraging New OP-3136 Phase 1 Data - Sahm
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - GlobeNewswire Inc.
Olema Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Olema Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Quiver Quantitative
Breast cancer-focused Olema plans 3 investor talks across May and June - Stock Titan
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Announces Target Price $52 - Moomoo
Olema Pharmaceuticals (OLMA) loses 33.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Olema Pharmaceuticals (OLMA) Deepens Trial Spend With Ample Cash Buffer Is Its Risk-Reward Now Clearer? - Sahm
Olema Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo
Bain Capital (OLMA) discloses 8.2% position including pre-funded warrant - Stock Titan
Janus Henderson (NASDAQ: OLMA) discloses 7.11M shares, 8.2% stake - Stock Titan
Olema: The Market Overreacted To Roche's SERD Failure - Seeking Alpha
Legal operations leadership role opens as Olema Pharmaceuticals launches search for senior manager - Traders Union
Olema Oncology (OLMA) Gains Attention with Upcoming Clinical Res - GuruFocus
Citi Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $62 - Moomoo
A Quick Look at Today's Ratings for Olema Pharmaceuticals(OLMA.US), With a Forecast Between $23 to $48 - Moomoo
Goldman Sachs Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
OLMA Maintained by Guggenheim -- Price Target Lowered to $35.00 - GuruFocus
OpenAI pushed this startup out of San Francisco, but it found a brand-new space elsewhere - The Business Journals
Guggenheim cuts Olema Pharmaceuticals stock price target on trial timing By Investing.com - Investing.com Canada
TradingKey - TradingKey
Olema Pharmaceuticals Q1 Net Loss Widens - Moomoo
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
Olema Oncology (OLMA) Focuses on Advancing Breast Cancer Treatme - GuruFocus
How to Value Olema Pharmaceuticals (OLMA) After Q1 2026 Earnings - GuruFocus
Olema Oncology Announces Q1 2026 Financial Results and Upcoming Phase 3 Breast Cancer Trial Data - Minichart
Olema Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Olema Oncology Announces First Quarter 2026 Financial and Operating Results on May 12 - geneonline.com
Olema Pharmaceuticals Ended 1Q With $505.3M Cash, Equivalents, Marketable Securities >OLMA - Moomoo
Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q1 Net Loss $0.52 a Share, vs. FactSet Est of $0.52 Loss - marketscreener.com
Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q1 Net Loss $0.52 a Share, Vs. FactSet Est of $0.52 Loss - Moomoo
Olema Pharmaceuticals, Inc. Q1 2026: Net income $(53.1)M, EPS $(0.52) — 10-Q Summary - TradingView
Olema Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Olema Pharmaceuticals (NASDAQ: OLMA) widens Q1 loss but ends quarter with $505M cash - Stock Titan
Olema Oncology Reports First Quarter 2026 Financial and Operating Results - The Manila Times
Olema Oncology (NASDAQ: OLMA) boosts trial spending ahead of key 2026 data - Stock Titan
Press Release: Olema Oncology Reports First Quarter 2026 Financial and Operating Results - Moomoo
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):